Santos Carlos E reported grant involving 19,676 shares of Legend Biotech Corp at $0.00 for $0 on Sep 21, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Sep 23, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
19,676Ordinary Shares
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
19,676Direct
Trade date
Sep 21, 2026Grant
Filed
Sep 23, 2026, 4:15 PM ET2-day reporting delay
Accession
0002097065-26-000005Code A · Transaction 228287
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 21, 2026Sell5,430$9.14−$49,630.20Trade 228288
2 transaction rows in this filing. Joint filers share the same rows.

LEGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LEGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +18%1w ago +0.4%1d ago −4.6%
Returns since7d +7.8%30d +2.4%90d180d1y

Footnotes in full

F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2: Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units. F3: The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.905 to $9.325 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.